Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ionis Pharmaceuticals, Inc.    IONS


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ionis Pharmaceuticals : and Akcea Recognize FCS Awareness Day with Global Community Efforts to Celebrate Unsung Heroes

11/09/2020 | 09:25am EST

BOSTON - Ionis Pharmaceuticals (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, today recognize the 3rd annual Familial Chylomicronemia Syndrome (FCS) Awareness Day, a global observance held each year on the first Friday in November to build broader awareness of the challenges associated with this debilitating, ultra-rare disease.

Together with members of the FCS community, Ionis and Akcea have made significant progress in efforts to help people around the world learn about FCS and the impact it has on patients, their families and caregivers.

'We are proud to join forces with the FCS community to bring awareness to this devastating disease. Today, we shine a light on the patients, caregivers and families who live with the burden of this disease and we celebrate the members of the global FCS community who are leading the charge to drive awareness of FCS,' said Kristina Bowyer, vice president of patient centric drug development at Ionis. 'Advocates including Melissa Goetz and Lindsey Sutton from the FCS Foundation, and Jill Prawer from Action FCS, are some of the many humble heroes whose tireless efforts to advocate on behalf of patients and families is inspiration for our work. Their strength and commitment, especially during a very challenging year, give our teams a renewed dedication to support their needs.'

FCS is a genetic disease caused by impaired function of the enzyme lipoprotein lipase (LPL), which results in elevated triglyceride levels and significant risk and disease burden. This may include unpredictable and potentially fatal acute pancreatitis as well as chronic complications due to permanent organ damage. It is estimated that there are between 3,000 to 5,000 people living with FCS worldwide. Patients must manage their triglyceride levels by adopting a strict, extremely low-fat diet of 10-20g of fat per day, which is incredibly challenging and does not remove the risk of pancreatitis and other symptoms of the disease.

To drive attention to FCS Awareness Day, employees from both Ionis and Akcea will participate in an FCS diet challenge where they must adhere to the strict, low-fat diet that patients live by every day for the entire FCS Awareness Day. The companies also encourage employees and members of the global FCS community to participate in a recipe challenge where they can share creative recipes including FCS-friendly foods. Ionis and Akcea plan to share their activities on social media using hashtags #FCSAwarenessDay, #chylomicronemia, #ActionFCS, and #LPLD. The recipes are available here.

'I have always lived with the challenges of the low-fat FCS diet and the impact it has had on me physically, emotionally and socially - I would often avoid social engagements with friends and family,' said Krish, a London resident who lives with FCS. 'I am grateful to companies like Akcea and Ionis for highlighting the unique challenges that people affected by FCS experience daily and their efforts to support patients. Together, we must continue to raise awareness of this challenging and debilitating rare disease on a global scale.'

About FCS

FCS is an ultra-rare disease caused by impaired function of the enzyme lipoprotein lipase (LPL) and characterized by severe hypertriglyceridemia (>880mg/dL or 10mmol/L) and a risk of unpredictable and potentially fatal acute pancreatitis. Because of limited LPL production or function, people with FCS cannot breakdown chylomicrons, lipoprotein particles that are 90 percent triglycerides. In addition to acute pancreatitis, FCS patients are at risk of chronic complications due to permanent organ damage, including chronic pancreatitis and pancreatogenic (type 3c) diabetes. They can experience daily symptoms including abdominal pain, generalized fatigue and impaired cognition that affect their ability to work. People with FCS also report major emotional and psychosocial effects including anxiety, social withdrawal, depression and brain fog.


Akcea Therapeutics, Inc. is a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA therapeutics. Akcea commercializes TEGSEDI (inotersen) and WAYLIVRA (volanesorsen), and with Ionis, is advancing a mature pipeline of novel medicines discovered by Ionis and based on Ionis' proprietary antisense technology. TEGSEDI is approved in the U.S., E.U., Canada and Brazil, and WAYLIVRA is approved in the E.U.


As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to potentially treat a broad range of disease, including neurological, cardio-renal, metabolic, infectious, and pulmonary diseases.


This press release includes forward-looking statements regarding Ionis' business, financial guidance and the therapeutic and commercial potential of WAYLIVRA and Ionis' technologies and products in development, including the business of Akcea Therapeutics, Inc., Ionis' wholly owned subsidiary. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2019, and the most recent Form 10-Q quarterly filing, which are on file with the SEC. Copies of these and other documents are available from the Company.


D. Wade Walke

Tel: 760-603-2741

Email: wwalke@ionisph.com

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
AKCEA THERAPEUTICS, INC. 0.17% 18.17 End-of-day quote.0.00%
IONIS PHARMACEUTICALS, INC. -1.98% 62.52 Delayed Quote.10.58%
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
01/12IONIS PHARMACEUTICALS : 2021 JP Morgan Presentation
01/11BIOGEN : Announces First Patient Treated in RESPOND Study Evaluating Benefit of ..
01/08BIOGEN : Treats First Patient in Study of SPINRAZA to Treat Children With Spinal..
01/07IONIS PHARMACEUTICALS : Appoints Eugene Schneider as Chief Clinical Development ..
01/07IONIS PHARMACEUTICALS : appoints Eugene Schneider, M.D., as executive vice presi..
01/05IONIS PHARMACEUTICALS : to present at 39th Annual J.P. Morgan Healthcare Confere..
2020IONIS PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K)
2020IONIS PHARMACEUTICALS : Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to f..
2020IONIS PHARMACEUTICALS : UBS Starts Ionis Pharmaceuticals at Sell With $34 Price ..
More news
Financials (USD)
Sales 2020 710 M - -
Net income 2020 -74,6 M - -
Net Debt 2020 145 M - -
P/E ratio 2020 -123x
Yield 2020 -
Capitalization 8 742 M 8 742 M -
EV / Sales 2020 12,5x
EV / Sales 2021 11,2x
Nbr of Employees 817
Free-Float 95,0%
Duration : Period :
Ionis Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IONIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 64,81 $
Last Close Price 62,52 $
Spread / Highest target 91,9%
Spread / Average Target 3,66%
Spread / Lowest Target -69,6%
EPS Revisions
Managers and Directors
Brett P. Monia Chief Executive Officer & Director
Stanley T. Crooke Executive Chairman
Joel Edwards Vice President-Corporate & Commercial Operations
Elizabeth L. Hougen Chief Financial Officer & SVP-Finance
C. Frank Bennett Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.45.35%60 120
LONZA GROUP AG5.49%50 227
CELLTRION, INC.-10.58%39 891
SEAGEN INC.-1.43%31 230